7th treatment shown to reduce risk in
September 2020
Lower risk for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols
combine complementary and synergistic treatments. * >10%
efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for
60+ treatments. c19early.org
|
|
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 365 (0.0%), control 1 of 365 (0.3%), NNT 365, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 1+ days of treatment, group sizes approximated.
|
|
risk of hospitalization, 50.0% lower, RR 0.50, p = 0.38, treatment 4 of 365 (1.1%), control 8 of 365 (2.2%), NNT 91, 1+ days of treatment, group sizes approximated.
|
|
risk of death, 66.6% lower, RR 0.33, p = 1.00, treatment 0 of 360 (0.0%), control 1 of 361 (0.3%), NNT 361, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >1 day of treatment, group sizes approximated.
|
|
risk of hospitalization, 71.3% lower, RR 0.29, p = 0.18, treatment 2 of 360 (0.6%), control 7 of 361 (1.9%), NNT 72, >1 day of treatment, group sizes approximated.
|
|
risk of death, 66.6% lower, RR 0.33, p = 1.00, treatment 0 of 346 (0.0%), control 1 of 347 (0.3%), NNT 347, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >7 days of treatment, group sizes approximated.
|
|
risk of hospitalization, 92.3% lower, RR 0.08, p = 0.03, treatment 0 of 346 (0.0%), control 6 of 347 (1.7%), NNT 58, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), >7 days of treatment, group sizes approximated.
|
|
risk of no viral clearance, 73.9% lower, RR 0.26, p < 0.001, treatment 365, control 365, group sizes approximated, day 7.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
